文献速递银屑病与炎症性皮肤病

局部治疗优化项目(TTOP)改善银屑病卡泊三醇/倍他米松凝胶的临床结局:一项64周多国随机IV期研究(1790例患者,PSO-TOP)

A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP).
PubMed 文献 · Br J Dermatol · 2017-06-06

PSO-TOP研究纳入1790例轻中度银屑病患者,随机1:1接受TTOP或标准管理,均使用卡泊三醇/倍他米松凝胶。TTOP患者认为结构化一对一沟通最重要。

要点

  • TTOP患者对治疗信息感知更好,但DLQI无差异。
  • 结构化医患沟通是TTOP最重要的元素。

核心结论

  • 随机接受TTOP干预的患者临床应答优于标准管理。
  • 改善医患沟通可能是提高银屑病局部治疗依从性的重要因素。

研究设计与样本

  • 多国、随机、IV期、研究者发起的PSO-TOP研究(NCT01587755)。
  • 1790例轻中度银屑病患者随机1:1接受TTOP或非TTOP管理。
  • 所有患者使用卡泊三醇/倍他米松 dipropionate 凝胶,每日一次8周,后续按需56周。

主要发现

  • TTOP组患者感觉对皮肤状况、治疗及依从性相关因素信息更充分的比率更高。
  • 两组DLQI无统计学差异。
  • TTOP患者认为与皮肤科医生/护士的结构化一对一沟通是最重要元素。

关键数值与推荐

  • 应答定义为PGA为「清除」或「几乎清除」。
  • 主要终点为8周应答率。

临床怎么用

  • 在银屑病局部治疗中可引入TTOP等结构化沟通工具以提高应答。
  • 重视医患一对一沟通作为改善依从性的手段。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Around two-thirds of patients with psoriasis do not adhere to topical treatment. The Topical Treatment Optimization Programme (TTOP), a five-element tool, includes guidance for the conversation between dermatologists/nurses and patients, patient information material, telephone/e-mail helpdesks and treatment reminders. It has been developed by patients and dermatologists to help increase adherence to treatment in psoriasis. OBJECTIVES: To compare TTOP with standard of care ('non-TTOP') within a large European investigator-initiated study, PSO-TOP (clinicaltrials.gov NCT01587755). METHODS: Patients with mild-to-moderate psoriasis received calcipotriol/betamethasone dipropionate gel as standardized study medication and were randomized 1 : 1 to either TTOP or non-TTOP management. Study medication was applied once daily for 8 weeks followed by 'as needed' application for an additional 56 weeks. Response was defined as a Physician's Global Assessment (PGA) of 'clear' or 'almost clear'. RESULTS: In 1790 patients (full analysis set), response rates after 8 weeks (primary objective) were significantly higher for TTOP (36·3%) than for non-TTOP (31·3%, P = 0·0267). Better clinical outcome was accompanied by higher rates of patients feeling well informed about their skin condition, treatment and other factors related to adherence, but the Dermatology Life Quality Index was not statistically different. TTOP patients regarded the structured one-to-one conversations with their dermatologist/nurse as the most important element of TTOP. CONCLUSIONS: Patients randomized to the TTOP intervention had a better clinical response than patients receiving standard of care. Improved communication between the healthcare provider and patient might be an important element in increasing adherence to topical therapy in psoriasis.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Reich K, Zschocke I, Bachelez H, et al. A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). Br J Dermatol. 2017. PMID: 28301043. doi:10.1111/bjd.15466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。